Investors

Key press releases

18 Nov 2021
13:44 E.S.T.

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

11 Nov 2021
17:19 E.S.T.

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

04 Nov 2021
14:51 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021

Key upcoming events

11 Dec 2021 ‐ 14 Dec 2021

63rd American Society of Hematology (ASH)

Learn more

14 Dec 2021 ‐ 16 Dec 2021

Cell Therapy Analytical Development Summit

Learn more

Key corporate presentation

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$9.3300

+0.1100 (1.1931%)

Prev. close: 9.2200
Volume: 184,119
High: 9.5700
Capitalization: 424.285M

€8.2850

+0.2650 (3.3042%)

Prev. close: 8.0200
Volume: 112,229
High: 8.3150
Capitalization: 376.763M

See stock information

Covering research analysts

Barclays - Gena Wang

Citi - Yigal Nochomovitz

Goldman Sachs - Salveen Richter& Elisabeth Webster

Guggenheim - Michael Schmidt & Kelsey Goodwin

Jefferies - Kelly Shi

Jones Trading - Soumit Roy

Kempen - Ingrid Gafanhão

Ladenburg – Wangzhi Li

Oddo BHF - Martial Descoutures

Oppenheimer – Hartaj Singh

Portzamparc – Christophe Dombu

RW Baird - Jack Allen

Wells Fargo – Nick Abbott

William Blair – Raju Prasad

Cellectis contact information

Eric Dutang
+1 (646) 630 1748

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89